Cyclafem 1/35 and Carcinoembryonic antigen increased - from FDA reports


Summary

There is no Carcinoembryonic antigen increased reported by people who take Cyclafem 1/35 yet. We study 2,148 people who have side effects while taking Cyclafem 1/35 from FDA. Find out below who they are, when they have Carcinoembryonic antigen increased and more.

What to expect?

If you take Cyclafem 1/35 and have Carcinoembryonic antigen increased, find out what symptoms you could have in 1 year or longer.

You are not alone!

Join a support group for people who take Cyclafem 1/35 and have Carcinoembryonic antigen increased

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA since 1977. Our tools are simple to use, anonymous and free. Start now >>>

Cyclafem 1/35

Cyclafem 1/35 has active ingredients of ethinyl estradiol; norethindrone. It is often used in birth control. (latest outcomes from Cyclafem 1/35 135 users)

Carcinoembryonic Antigen Increased

Carcinoembryonic antigen increased has been reported by people with colon cancer, breast cancer, breast cancer metastatic, high blood pressure, metastases to bone (latest reports from 920 Carcinoembryonic antigen increased patients).

On Feb, 27, 2017

No report is found.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you have Carcinoembryonic antigen increased when taking Cyclafem 1/35?

Browse all side effects of Cyclafem 1/35

a b c d e f g h i j k l m n o p q r s t u v w x y z

Drugs that are associated with Carcinoembryonic antigen increased

Carcinoembryonic antigen increased

Could your condition cause Carcinoembryonic antigen increased

Carcinoembryonic antigen increased

Related studies